Rallybio Corp (RLYB)

Rallybio Corp (RLYB) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $89.9M; returns 1 day +1.5%, 1 week +2.2%, 1 year +246.7%.

Rallybio Corp (RLYB) is a clinical-stage biotechnology company dedicated to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Their primary focus is on complement dysregulation and hematology. As of Q3 2025, Rallybio reported total revenue of $0.2 million, derived from collaboration agreements.

Groups RLYB belongs to

• Biotechnology
• Recent Reverse Splits
• Clinical Stage Biotech
• Healthcare
• Rare Diseases
• Clinical Stage
• Biopharmaceutical
• Hematology
• Unmet Medical Needs
• Life Sciences

RLYB financial model: income statement, cash flow and balance sheet